You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline Snapshot as of

  • Discovery Projects
  • Phase 1
    13
  • Phase 2
    5
  • Phase 3
    20
  • Registration
    4
  • Total42
 
Compound Name
Indication
Phase
Submission Typesort ascending
Compound Type
PF-04136309
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
WRD
Mechanism of Action:
CCR2 (Chemokine receptor 2) Antagonist
Go to clinical trial
Pancreatic Cancer Phase 1 New Molecular Entity Small Molecule
PF-04518600
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
OX40 receptor Agonist
Go to clinical trial
Cancer, Combo w/ avelumab (PD-L1) (Biologic) Phase 1 New Molecular Entity Biologic
PF-05082566
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CD137 Agonist
Go to clinical trial
Cancer (Biologic), Combo w/ Merck's Keytruda (PD-1, pembrolizumab), Combo w/ Kyowa Hakko Kirin's anti-CCR4 antibody (mogamulizumab) Phase 1 New Molecular Entity Biologic
PF-06647020
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
protein tyrosine kinase 7 (PTK7) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
PF-06647263
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
ephrin-A4 (EFNA4) Targeted Cytotoxicity
Go to clinical trial
Cancer (Biologic) Phase 1 New Molecular Entity Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
2nd Line Metastatic Merkel Cell Carcinoma (E.U.) (Biologic) Registration New Molecular Entity Biologic
  •